Treatment of Enteroaggregative E. coli (EAEC) Infection
For EAEC diarrhea, rifaximin is the preferred first-line antibiotic, with azithromycin as an effective alternative, particularly for travelers to India and Africa where quinolone resistance is high.
Primary Treatment Recommendations
Antibiotic Therapy
Rifaximin remains highly effective against EAEC with low resistance rates 1, 2, 3. In a placebo-controlled trial, rifaximin significantly shortened illness duration in EAEC diarrhea (median 22 hours vs. 72 hours with placebo, p=0.03) 3.
Azithromycin is an excellent alternative, particularly effective for shortening the course of EAEC diarrhea 4, 5. However, resistance rates exceed 25% in isolates from Southeast Asia/India and Africa 1, so consider local resistance patterns.
Avoid fluoroquinolones (ciprofloxacin, levofloxacin) for travelers to India and sub-Saharan Africa, where quinolone resistance in EAEC has increased dramatically over recent decades 1, 2.
Supportive Care
All patients require adequate oral rehydration therapy as the foundation of treatment 4. Antimotility agents may be considered for non-bloody diarrhea in adults 6.
Treatment Algorithm
For mild, self-limited diarrhea:
- Oral rehydration alone
- Monitor for resolution within 3-7 days
For moderate-to-severe or persistent diarrhea (>3 days):
- First choice: Rifaximin (standard traveler's diarrhea dosing)
- Second choice: Azithromycin (if rifaximin unavailable or patient traveling to high-resistance areas)
- Continue oral rehydration
For severe dehydrating illness despite adequate rehydration:
- Initiate antimicrobials immediately
- Azithromycin or rifaximin based on travel history
- Consider hospitalization for IV fluids if needed
Geographic Considerations
Travel to India or sub-Saharan Africa: Quinolone resistance is extremely high; use rifaximin or azithromycin 1.
Travel to Central America: Be aware of emerging cephamycinase resistance, though rifaximin and azithromycin remain effective 1.
Southeast Asia: Azithromycin resistance exceeds 25%; rifaximin is preferred 1.
Important Clinical Caveats
Ampicillin and trimethoprim-sulfamethoxazole resistance frequently exceeds 50% across all regions—avoid these agents 7.
EAEC produces strong biofilms that can complicate treatment and contribute to persistent infection 2, 8, 9. This may explain why some infections persist despite appropriate therapy.
Not all EAEC infections are symptomatic—heterogeneity in strains and host immune responses means some individuals may be asymptomatic carriers 5.
Extended-spectrum β-lactamase (ESBL)-producing EAEC strains (particularly ST38 and ST131) are increasingly prevalent 1. Third-generation cephalosporins should not be relied upon empirically.
Multiplex PCR panels can now detect EAEC rapidly, but clinical correlation is essential as nucleic acid detection doesn't always indicate viable, clinically relevant organisms 6.
Special Populations
Children: Azithromycin and rifaximin are recommended for severe or persistent illness after adequate oral rehydration 4. All children require careful fluid management.
Immunocompromised patients: Consider earlier antimicrobial intervention and longer treatment courses. Multiplex diagnostic assays may be particularly useful in this population 6.